February 2017 FDA Recall Drug by Teva Pharmaceuticals Usa
D-0511-2017 - Failed Dissolution Specifications

This Class III drug recall was voluntarily initiated by Teva Pharmaceuticals Usa on February 17, 2017 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0511-2017

Reason for Recall
Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.
Initiated
02-17-2017
Reported
03-15-2017
Quantity
25,916 cartons

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Teva Pharmaceuticals USA
Nationwide in the United States and Puerto Rico
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Batch or Lot Expiration Information

Lot# 34025762A, Exp 06/17